Intervention
Dapagliflozin 10 MG
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 13 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
13 shownA Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health RecordNCT06642272 · 2024-10-10
RECRUITINGThe Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant RecipientsNCT05938712 · 2023-10-24
RECRUITINGSodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF PatientsNCT06065280 · 2022-11-01
COMPLETEDSGLT2 Inhibition in HemodialysisNCT05179668 · 2022-10-01
COMPLETEDEmpagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart FailureNCT05776043 · 2022-03-15
UNKNOWNEffects of SGLT2 Inhibitor on Type 2 Diabetic Patients Undergoing Cardiac SurgeryNCT04340908 · 2021-01-01
UNKNOWNEfficacy and Safety of Dapagliflozin in Acute Heart FailureNCT04298229 · 2020-04-01
COMPLETEDValue of SGLT2 Inhibitor (Dapagliflozin) as an Added Therapy in Diabetic Patients With Heart Failure With Reduced Ejection Fraction; Randomized Controlled Clinical TrialNCT04304560 · 2020-03-01
UNKNOWNDapagliflozin Effect on Glucose Variability in Patients Post Bariatric SurgeryNCT07515391 · 2019-10-22
ENROLLING_BY_INVITATIONTherapeutic Effect of Dapagliflozin Combined With CSII on Newly Diagnosed Type 2 Diabetes MellitusNCT04120623 · 2019-10-01
UNKNOWNSGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 DiabetesNCT03982381 · 2019-09-05
COMPLETEDEffectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.NCT03970044 · 2019-07-02
COMPLETEDPhthalates Exposure in Type 2 Diabetic Patients and Diuretic TherapyNCT04242758 · 2019-06-04
UNKNOWNCommon conditions
Diabetes Mellitus, Type 25Heart Failure3Acute Decompensated Heart Failure1Bariatric Surgery Candidate1Cardiac Surgery1Cardiomyopathies1Chronic Kidney Disease1Chronic Kidney Diseases1Diabete Type 21Glucose Metabolism Disorders1Heart Failure With Reduced Ejection Fraction (HFrEF)1Hemodialysis1Kidney Failure1Kidney Transplant Recipients1Left Ventricular Hypertrophy1Reduced Ejection Fraction Heart Failure1Renal Function Disorder1Type 2 Diabetes1Type 2 Diabetes Mellitus1Type2 Diabetes1
Leading sponsors
Damanhour University
2
Consano Clinical Research, LLC
1
Dasman Diabetes Institute
1
Herlev and Gentofte Hospital
1
Hongchang Guo
1
Medical University of Vienna
1
Medical University of Warsaw
1
Nanjing First Hospital, Nanjing Medical University
1
University Health Network, Toronto
1
University of Pisa
1
Uppsala University
1
Vanderbilt University Medical Center
1
Trial status mix
COMPLETED5
UNKNOWN5
RECRUITING2
ENROLLING_BY_INVITATION1
Phase mix
PHASE46
PHASE24
PHASE32
NA1
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.